
Vivani Medical Inc
NASDAQ:VANI

Vivani Medical Inc
Gross Profit
Vivani Medical Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Vivani Medical Inc
NASDAQ:VANI
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Becton Dickinson and Co
NYSE:BDX
|
Gross Profit
$9.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
![]() |
Boston Scientific Corp
NYSE:BSX
|
Gross Profit
$11.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
![]() |
Stryker Corp
NYSE:SYK
|
Gross Profit
$14.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
![]() |
Abbott Laboratories
NYSE:ABT
|
Gross Profit
$23.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
Gross Profit
$5.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
Vivani Medical Inc
Glance View
Vivani Medical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Emeryville, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Vivani Medical, Inc., formerly Second Sight Medical Products, Inc., is a developer of implantable visual prosthetics that creates an artificial form of useful vision for blind individuals. The firm is the combination of Nano Precision Medical, Inc. (NPM) and Second Sight Medical Products, Inc. NPM is a biopharmaceutical business that develops miniaturized, subdermal drug implants utilizing its NanoPortal technology to enable long-term, near constant-rate delivery of medicines to treat chronic diseases. Its divisions include Drug Implant & Visual Protheses division. The firm's Drug Implant division is developing a portfolio of miniature drug implants which utilize its NanoPortal drug implant technology. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. The firm's Visual Protheses division is developing implantable visual prostheses devices that are intended to deliver useful artificial vision to blind individuals.
